Olanzapine News and Research

RSS
Olanzapine (trade names Zyprexa, Zyprexa Zydis, Zalasta, Zolafren, Olzapin, Rexapin or in combination with fluoxetine Symbyax) is an atypical antipsychotic, approved by the FDA for the treatment of schizophrenia and bipolar disorder.
New approaches to prevent or treat antipsychotic-induced supersensitivity psychosis

New approaches to prevent or treat antipsychotic-induced supersensitivity psychosis

Antipsychotic drug could help reduce nausea and vomiting caused by chemotherapy

Antipsychotic drug could help reduce nausea and vomiting caused by chemotherapy

Study compares aripiprazole and quetiapine for treatment of schizophrenia

Study compares aripiprazole and quetiapine for treatment of schizophrenia

Antipsychotic drugs may do significantly more harm to Parkinson's disease patients

Antipsychotic drugs may do significantly more harm to Parkinson's disease patients

Long-term lithium exposure does not increase renal dysfunction risk

Long-term lithium exposure does not increase renal dysfunction risk

Lithium can be safe, effective for children suffering from bipolar disorder

Lithium can be safe, effective for children suffering from bipolar disorder

Medicaid could save billions as patents for several blockbuster antipsychotic medications expire

Medicaid could save billions as patents for several blockbuster antipsychotic medications expire

Added benefit of lurasidone drug not proven for schizophrenia

Added benefit of lurasidone drug not proven for schizophrenia

Endogenous cannabinoids linked to weight gain in people with schizophrenia

Endogenous cannabinoids linked to weight gain in people with schizophrenia

People with first-episode psychosis may benefit from medication treatment changes, study finds

People with first-episode psychosis may benefit from medication treatment changes, study finds

Janssen announces submission of NDA for three-month paliperidone palmitate

Janssen announces submission of NDA for three-month paliperidone palmitate

Alkermes initiates second ALKS 3831 Phase 2 clinical study for treatment of schizophrenia

Alkermes initiates second ALKS 3831 Phase 2 clinical study for treatment of schizophrenia

Mylan releases generic version of Zyprexa Zydis Tablets

Mylan releases generic version of Zyprexa Zydis Tablets

Forest Laboratories to acquire exclusive rights in the U.S. for Saphris sublingual tablets

Forest Laboratories to acquire exclusive rights in the U.S. for Saphris sublingual tablets

Antipsychotic drugs for children with behavioral problems may put at risk for type 2 diabetes

Antipsychotic drugs for children with behavioral problems may put at risk for type 2 diabetes

Alkermes reports positive results from phase 1 study of ALKS 3831 for treatment of schizophrenia

Alkermes reports positive results from phase 1 study of ALKS 3831 for treatment of schizophrenia

Off label atypical antipsychotic use lacks safety and effectiveness in patients over 40

Off label atypical antipsychotic use lacks safety and effectiveness in patients over 40

FDA accepts Sunovion’s two LATUDA sNDAs for review

FDA accepts Sunovion’s two LATUDA sNDAs for review

Adjunctive drugs hasten sedation in the emergency department

Adjunctive drugs hasten sedation in the emergency department

Antipsychotic use in pregnancy should be closely monitored

Antipsychotic use in pregnancy should be closely monitored